News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
101 WIXX Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up …
Bitcoin mining company Riot Platforms recently secured a significant $9 billion, 20-year agreement to provide AI compute services to Anthropic, with potential for an additional $7 billion from extensions. This deal highlights a growing trend among Bitcoin miners to pivot their data center infrastructure …
Riot Platforms has signed a significant $9 billion compute agreement with AI company Anthropic, involving 191 megawatts of capacity from Riot's Rockdale, Texas facility over 20 years. This deal marks a strategic pivot for Riot away from Bitcoin mining and towards AI data-center infrastructure, …
Wall Street Zen has upgraded Atara Biotherapeutics (NASDAQ:ATRA) from "Sell" to "Hold," reflecting an average "Hold" consensus among analysts with an average price target of $9.50. Despite the upgrade, ATRA shares opened down 4.9% at $8.09, with the company reporting a quarterly loss of …
This article provides current stock price information for First Tracks Biotherapeutics, Inc. (TRAX) on MEXC, detailing its live price, market data, and recent performance. It also includes instructions on how to buy TRAX on MEXC and offers a company overview, including its focus on …
Iovance Biotherapeutics, Inc. stock has rallied over 130% in 2026, closing at $6.98, but is showing strong overbought signals across multiple timeframes with daily RSI at 73.02. While the daily trend remains bullish due to strong EMA alignment and positive MACD, the elevated RSI …
Sanjit Biswas, CEO of Samsara Inc. (NASDAQ:IOT), sold approximately $10.1 million worth of Class A Common Stock through pre-arranged trading plans between August 4 and August 6, 2026. These sales, conducted via the Biswas Family Trust and other trusts, involved a total of 262,900 …
Maxim Group has reiterated its Buy rating for Moleculin Biotech (MBRX.US) but has reduced the target price for the stock to $2. This adjustment reflects a revised outlook on the company's valuation while maintaining a positive long-term perspective.
Biote Corp.'s executive chairman, Marc Beer, recently purchased 131,950 shares of Class A Common Stock worth over $202,000. These transactions occurred on August 10 and 11, 2026, amidst a 44% year-to-date decline in the stock's value. Despite a recent revenue decline reported in Q2 …
This article from Benzinga reviews the performance of several key stocks, highlighting both bullish and bearish sentiments from the past week. It covers Riot Platforms' Q2 success and data center deal, Firefly Aerospace's significant revenue surge, and the rebound of SpaceX shares. Conversely, it …
5 Revealing Analyst Questions From Marriott Vacations's Q2 Earnings Call Marriott Vacations delivered a second quarter that surpassed Wall Street expectations, with management emphasizing the impact of new commercial strategies and owner engagement initiatives. CEO Matthew Avril highlighted that contract sales rose 22% year …
Royal Bank of Canada upgraded Krystal Biotech (NASDAQ:KRYS) to a "moderate buy" rating, aligning with a generally bullish analyst consensus. The company, which has a market capitalization of $9.83 billion, recently reported quarterly earnings that beat expectations but revenue that slightly missed. Insider selling …
Krystal Biotech (KRYS) Director Dino Rossi sold 25,000 shares of the company on August 14, 2026, for approximately $8.23 million, reducing his direct ownership to 50,000 shares. This sale continues a trend of insider selling over the past year, with no insider buys reported, …
Wall Street Zen has downgraded Fortress Biotech (NASDAQ:FBIO) from a "strong-buy" to a "hold" rating. The stock currently holds an average "Hold" rating among analysts with a consensus price target of $17.00. Fortress Biotech recently reported stronger-than-expected quarterly earnings, with EPS of -$0.08 and …
Wall Street Zen upgraded Puma Biotechnology (NASDAQ:PBYI) from a "buy" to a "strong-buy" rating, despite the broader analyst consensus remaining "hold" with a $6.00 price target. The company reported strong quarterly earnings, beating EPS and revenue estimates, though insiders have sold a significant number …
Wall Street Zen has upgraded Marriott Vacations Worldwide (NYSE:VAC) stock rating from "hold" to "buy." The company also reported strong quarterly earnings, beating analyst estimates with an EPS of $2.31 and revenue of $1.32 billion, an increase of 5.9% year-over-year. Institutional investors hold a …
This article analyzes Atara Biotherapeutics Inc. (NASDAQ: ATRA) for tactical trading, highlighting a strong near and mid-term sentiment despite a weak long-term outlook. It identifies an exceptional 234.0:1 risk-reward setup targeting a 70.2% gain against 0.3% risk. The analysis also provides specific institutional trading …
Woodline Partners LP has filed an amended Schedule 13G, disclosing a beneficial ownership of 5,455,355 shares, or 6.8%, of SAB Biotherapeutics, Inc. common stock. This stake includes common shares and shares issuable from Series B Preferred Stock underlying Enrollment and Data Release Warrants. The …
Krystal Biotech (KRYS.US) Director, Daniel Meyer, sold 84,200 shares of common stock on August 13, 2026, for a total of $8.23 million. The shares were sold at an average price of $97.75. Following this transaction, Meyer directly owns 10,000 shares of the company.
Moleculin Biotech (MBRX) reported a net loss of $7.6 million for Q2 2026, with a significant improvement in loss per share, narrowing to $1.40 from $12.25 in Q2 2025. The company, focused on therapeutic candidates for tumors and viruses, generated no revenue but continued …
Search by ticker symbol or company name and select a result to open its chart.